Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New Interim CAR-T Data Support Kite’s BLA Submission Plans

Executive Summary

Kite Pharma Inc. executives reiterated plans on Sept. 26 to pursue US FDA approval this year for the chimeric antigen receptor T cell (CAR-T) therapy known as KTE-C19, keeping the company on track to seek accelerated approval for a form of advanced lymphoma before any of its competitors.

Advertisement

Related Content

ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again
Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks
Novartis Tests Global Manufacturing Process For CAR-T Therapy
INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve
CAR-T Update: Kite's Filing Coming Soon
Juno ROCKETs On Fast Clinical Hold Resolution
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register